Progressive Keratoconus or Ectasia Treatment Plan
Keratoconus, Ectasia
About this trial
This is an expanded access trial for Keratoconus focused on measuring Keratoconus, Ectasia, UVA light, riboflavin, post-LASIK (laser in situ keratomileusis), pellucid marginal degeneration, irregular astigmatism
Eligibility Criteria
Inclusion Criteria:
Subjects who have one or both eyes that meet all of the following criteria will be considered candidates for this treatment:
For Keratoconus and Post Refractive Surgery Ectasia:
- 16 years of age or older
Having a diagnosis of keratoconus with one or more of the following changes over a period of 24 months or less.
- An increase of > 1.00 D in the steepest keratometry value (or sim K)
- An increase of > 1.00 D in regular astigmatism evaluated by subjective manifest refraction
- A myopic shift (decrease in the spherical equivalent) of > 0.50 D on subjective manifest refraction
- Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.
- Presence of central or inferior steepening on the Pentacam map.
- Axial topography consistent with keratoconus
Slit lamp findings associated with keratoconus must be documented:
- Fleischer ring
- Vogt striae
- Corneal thinning
- Corneal scarring
- Contact Lens Wearers Only: Removal of contact lenses are required prior to the screening
- Signed written informed consent
Exclusion Criteria:
All subjects meeting any of the following criteria will be excluded from this treatment:
- No evidence of progression.
- Excessively thin corneas.
Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:
- History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)
- Clinically significant corneal scarring in the proposed treatment zone
- A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.
- A known sensitivity to treatment medications
- Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.
Sites / Locations
- Edward Harkness Eye Institute-Columbia University Medical Center